Drugs / G-CSF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02835794 Background | Aug 2016 → Dec 2018 | myelodysplastic syndrome | University of Florida | Withdrawn | No outcome recorded Stop: Business |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-06-06 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Successful Results of Phase III Study of Its Long-Acting G-CSF Product (Lipegfilgrastim) in Breast Cancer Patients tevapharm.com ↗ |
| 2010-09-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Provides Update on Status of Neutroval™ (G-CSF) Biologics License Application Submitted to the U.S. Food and Drug Administration tevapharm.com ↗ |
| 2008-02-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva's Developed G-CSF is the First Biosimilar to Receive a Positive Opinion from European Union Regulators tevapharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02835794 ↗ |
| Route | Subcutaneous | “G-CSF 5mcg/kg subcutaneous daily” NCT02835794 ↗ |